Stephen A. Brown

Stephen A. Brown

Auto-generated profile, based on publicly available information

Stephen A. Brown

Lexington Veterans Administration Medical Center and Department of Medicine, University of Kentucky, Lexington, Kentucky 40511, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2009 in Life Sciences
Verified
Journal Article
Closed access
LMLeonid N Maslov
Leonid N Maslov
YLYury B. Lishmanov
Yury B. Lishmanov
POPeter R. Oeltgen
Peter R. Oeltgen
EBEva I. Barzakh
Eva I. Barzakh
AKAndrey V. Krylatov
Andrey V. Krylatov
SBStephen A. Brown
Stephen A. Brown

2 November 2010 in Academic Emergency Medicine
Verified
Journal Article
Open access
PDF file
LMLeonid N Maslov
Leonid N Maslov
YLYury B. Lishmanov
Yury B. Lishmanov
POPeter R. Oeltgen
Peter R. Oeltgen
EBEva I. Barzakh
Eva I. Barzakh
AKAndrey V. Krylatov
Andrey V. Krylatov
SBStephen A. Brown
Stephen A. Brown
Objectives: This study was conducted to test the hypothesis that opioid receptor (OR)‐mediated cardioprotection is agonist specific when administered prior to coronary artery occlusion and reperfusion in a rat model.Methods: Anesthetized open‐chest male Wistar rats were subjected to 45 minutes of left coronary artery occlusion and 2 hours of reperfusion. Opioid agonists were infused 15 minutes prior to coronary artery occlusion. Two control groups and 15 opioid‐treated groups were studied. Controls were infused with either saline alone (n = 16) or dimethyl sulfoxide plus hydroxypropyl‐β‐cyclodextrin in saline (n = 19). The μ‐selective agonist DAMGO was infused at either 150 nmol/kg (n = 15) or 1500 nmol/kg (n = 14), and dermorphin‐H was infused at 150 nmol/kg (n = 14). The δ1‐selective agonistd‐Pen2,5enkephalin (DPDPE) was infused at 150 nmol/kg (n = 16) or 1500 nmol/kg (n = 14). The δ2‐selective agonists deltorphin II (n = 16), deltorphin‐Dvariant(n = 15), and deltorphin‐E (n = 14) were infused at 150 nmol/kg. The selective κ1opioid agonist U‐50488 was infused at 240 nmol/kg (n = 14), 1500 nmol/kg (n = 14), and 2,400 nmol/kg (n = 14). The selective κ2opioid agonist GR‐89696 was infused at 150 nmol/kg (n = 14) and 1500 nmol/kg (n = 15). Orphinan FQ (nociceptin), also referred to as OR‐like 1 (ORL1), was infused at 220 nmol/kg (n = 15) and 1500 nmol/kg (n = 15). The infarct size/area at risk (IS/AAR) ratio was determined after reperfusion by negative staining with patent blue violet dye. Hemodynamic parameters including heart rate, mean arterial blood pressure (MAP), and rate pressure product (RPP) were determined.Results: Pretreatment with the δ2OR agonist deltorphin II (150 nmol/kg) significantly reduced the IS/AAR ratio, while deltorphin‐Dvariantand deltorphin‐E did not exhibit an infarct‐sparing effect at that treatment dose. Activation of δ1OR by DPDPE, κ1OR by U‐50488, κ2OR by GR‐89696, μ OR by DAMGO, dermorphin‐H, and nociceptin had no effect on the IS/AAR ratio. U‐50488 at 2,400 nmol/L induced a bradycardic effect. All other opioids had no effect on hemodynamic parameters at the doses tested.Conclusions: Peripheral δ2OR activation by deltorphin II induces infarct size reduction in this animal model. Agonists of μ, δ1, κ1, κ2, and nociceptin receptors at the doses tested did not induce cardiac tolerance to ischemia/reperfusion injury in vivo.ACADEMIC EMERGENCY MEDICINE 2010; 17:1239–1246 © 2010 by the Society for Academic Emergency Medicine